Video

Dr. Wolchock on the Phase III CheckMate-067 Melanoma Findings

Jedd Wolchok, MD, PhD, chief, melanoma and immunotherapeutics service and Lloyd J. Old Chair for clinical investigation at Memorial Sloan Kettering Cancer Center, discusses the findings of the Phase III CheckMate-067 trial.

Jedd Wolchok, MD, PhD, chief, melanoma and immunotherapeutics service and Lloyd J. Old Chair for clinical investigation at Memorial Sloan Kettering Cancer Center, discusses the findings of the Phase III CheckMate-067 trial.

The trial looked at nivolumab (Opdivo ) and ipilimumab (Yervoy) versus nivolumab monotherapy versus ipilimumab monotherapy in patients with previously untreated advanced melanoma.

There was a good balance between safety and efficacy in the combination cohort, says Wolchok. The combination cohort had the highest response rate and the longest progression-free survival. The therapy was delivered at 137 sites globally to 935 patients, one-third whom received the combination. Despite this large group, there were no therapy-related deaths, says Wolchok.

Of the 37% of patients who stopped treatment due to toxicities, 67.5% of those patients had an objective response, and half of those experienced that response after they stopped treatment. The trial’s successes can serve as a guideline for how to use this treatment if it should become available, says Wolchok.

<<<

View more from the 2015 ASCO Annual Meeting

Related Videos
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Kathleen N. Moore, MD, MS
Dana M. Chase, MD
Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center
Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine
R. Wendel Naumann, MD, professor and director of gynecologic oncology research, and associate medical director of clinical trials, Levine Cancer Institute, Atrium Health
Stéphanie Lheureux, MD, PhD, clinician investigator, Cancer Clinical Research Unit, Princess Margaret Cancer Centre